Biogen, Inc. is proposing that Medicare provide “full coverage” of Aduhelm and is offering to conduct several real-world evidence studies to collect additional data about its Alzheimer’s drug.
If adopted, the proposal would represent a significant reversal of the Centers for Medicare and Medicaid Services’ draft national coverage determination, which offered extremely limited coverage of Aduhelm in narrowly tailored randomized controlled trials
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?